News
Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines generated a strong immune response in ...
Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...
Novavax's combo and standalone flu vaccines showed strong immune responses and good safety in a Phase 3 trial of adults 65 ...
The Gaithersburg, Md., biotechnology company said Wednesday that results of the initial cohort of vaccines showed both the Covid-19-influenza combination and flu-vaccine candidates induced immune ...
The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety ...
Novavax (NasdaqGS:NVAX) recently reported initial results from its Phase 3 trial for its COVID-19-Influenza Combination and seasonal influenza vaccines, which showed immune responses comparable to ...
Novavax's experimental COVID-19-influenza combination and standalone influenza vaccines showed strong immune responses in ...
COVID-19 appears to be on the rise in some parts of California as a new, highly contagious subvariant — featuring “razor ...
The abrupt termination of the 17 panelists guiding the CDC’s vaccine recommendations could yield a new committee more aligned ...
The American Pharmacists Association announced Monday it will withhold endorsement of the CDC's updated immunization schedule ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results